3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
166
Cisplatin
112
Cetuximab
76
Nivolumab
52
Carboplatin
51
Fluorouracil
48
Paclitaxel
42
Docetaxel
37
Gemcitabine
30
Radiotherapy
28
Capecitabine
19
Cyclophosphamide
18
durvalumab
17
Injections
17
lenvatinib
16
atezolizumab
16
cemiplimab
15
spartalizumab
13
fludarabine
13
avelumab
12
Ipilimumab
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
11
Oxaliplatin
10
Gefitinib
10
tremelimumab
9
Drug Therapy
9
tislelizumab
8
epacadostat
8
budigalimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
ficlatuzumab
×
Head & Neck
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled